Advertisement

Topics

Visterra begins phase 1 clinical study of monoclonal antibody VIS649

04:07 EST 9 Nov 2018 | Pharmaceutical Business Review

VIS649 is a monoclonal antibody targeting the B-cell growth factor APRIL (A Proliferation Inducing Ligand) for the potential treatment of imumuglobulin A nephropathy (IgA nephropathy or IgAN), one

The post Visterra begins phase 1 clinical study of monoclonal antibody VIS649 appeared first on Pharma Business review.

Original Article: Visterra begins phase 1 clinical study of monoclonal antibody VIS649

NEXT ARTICLE

More From BioPortfolio on "Visterra begins phase 1 clinical study of monoclonal antibody VIS649"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...